|
By Martha Rosenberg, AlterNet
Posted on December 6, 2011,
It used to be joked that a consultant is someone who borrows your watch to tell you what time it is. These days, the opportunist is Big Pharma, which raises your insurance premiums and taxes while providing you “low-priced” drugs that you paid for.
How did Pharma get a good third of the United States taking antidepressants, statins, and Purple Pills, albeit at low prices? By selling the diseases of depression, high cholesterol, and gastroesophageal reflux disease, or GERD. Supply-driven marketing, also known as “Have Drug — Need Disease and Patients,” not only turns the nation into pill-popping hypochondriacs, it distracts from Pharma’s drought of real drugs for real medical problems.
Of course, not all diseases are Wall Street pleasers. To be a true blockbuster disease, a condition must (1) really exist but have huge diagnostic “wiggle room” and no clear-cut test, (2) be potentially serious with “silent symptoms” said to “only get worse” if untreated, (3) be “under-recognized,” “under-reported” with “barriers” to treatment, (4) explain hitherto vague health problems a patient has had, (5) have a catchy name — ED, ADHD, RLS, Low T or IBS — and instant medical identity, and (6) need an expensive new drug that has no generic equivalent.
Here are some potential blockbuster diseases Pharma hopes you get in 2012.
Adult ADHD
Everyday problems labeled as “depression” sailed Pharma through the last two decades. You weren’t sad, mad, scared, confused, remorseful, grieving, or even exploited. You were depressed, and there was a pill for that. But depression peaked just like the Atkins Diet and the Macarena. Luckily, there is adult ADHD (Attention Deficit Hyperactivity Disorder), which has doubled in women 45 to 65 and tripled in men and women 20 to 44, according to the Wall Street Journal.
Like depression, adult ADHD is a catch-all category. “Is It ADHD or Menopause?” asks an article in Additude, a magazine devoted exclusively to ADHD. “ADD and Alzheimer’s: Are These Diseases Related?” asks another article in the same magazine.
“I’m Depressed. Could it be ADHD?” says an ad in Psychiatric News, showing a pretty but pouting young woman. In the same publication, another ad titled “Broken Promises” says, “Adults with ADHD were nearly 2x more likely to have been divorced,” while exhorting doctors to “screen for ADHD.”
Adults with ADHD are often “less responsible, reliable, resourceful, goal-oriented, and self-confident, and they find it difficult to define, set, and pursue meaningful internal goals,” says an article cowritten by Harvard child psychiatrist Dr. Joseph Biederman, who is credited with putting “pediatric bipolar disorder” on the map. They “show tendencies to being self-absorbed, intolerant, critical, unhelpful, and opportunistic,” and “tend to be inconsiderate of other people’s rights or feelings,” says the article, describing most people’s brothers-in-law.
Adults with ADHD will have trouble keeping a job and get worse without treatment, says WebMD, tapping into the second requirement of a blockbuster disease — symptoms worsen without pills. “Adults with ADHD may have difficulty following directions, remembering information, concentrating, organizing tasks, or completing work within time limits,” according to the website, whose original partner was Eli Lilly.
How did Pharma get five million kids and now, maybe, their parents on ADHD meds? Ads on 26- by 20-foot screens in Times Square that ask “Can’t focus? Can’t sit still? Could you or your child have ADHD?” four times an hour couldn’t hurt. (Bet no one had trouble focusing on that!)
Still, convincing adults they aren’t sleep deficient or bored but have ADHD is only half the battle. Pharma also has to convince kids who grew up diagnosed as ADHD not to quit their meds, says Mike Cola of Shire (which makes the ADHD drugs Intuniv, Adderall XR, Vyvanse, and the Daytrana patch). “We know that we lose a significant number of patients in the late teen years, early 20s, as they kind of fall out of the system based on the fact that they no longer go to a pediatrician.”
A Shire ad in Northwestern University’s student paper this year takes the issue head on. “I remember being the kid with ADHD. Truth is, I still have it,” says the headline splashed across a photo of Adam Levine, the lead singer of Maroon 5. “It’s Your ADHD. Own It,” was the tagline. (Was “Stay Sick” the runner-up?)
Of course, pushing speed on college kids (or anyone, for that matter) isn’t too hard. Why else do meth dealers say, “First taste free”? But Pharma is so eager to retain its pediatric ADHD market, it has funded for-credit courses for doctors, such as “Identifying, Diagnosing, and Managing ADHD in College Students” and “ADHD in College: Seeking and Receiving Care During the Transition From Child to Adult.”
To make sure no one thinks ADHD is a made-up disease, WebMD shows color-enhanced Pet scans of the brains of a normal person and an ADHD sufferer (flanked by an ad for Vyvanse). But it is doubtful the scans are really different, says psychiatrist Dr. Phillip Sinaikin, author of Psychiatryland. And even if they are, it proves nothing.
“The crux of the matter is that there is simply no definitive understanding of how neuronal activity is related to subjective consciousness, the age-old unsolved body/mind relationship,” Sinaikin told AlterNet. “We have not advanced beyond phrenology, and this article in WebMD is simply the worst kind of manipulation by the drug industry to sell their overpriced products, in this case a desperate effort by Shire to maintain a market share when Adderall goes generic.”
Rheumatoid Arthritis
Rheumatoid arthritis is a serious and dangerous disease. But so are Pharma’s immune-suppressing biologic drugs like Remicade, Enbrel, and Humira, which are pushed to treat it. While RA attacks the body’s own tissues, leading to inflammation of the joints, surrounding tissues, and organs, immune suppressors can invite cancers, lethal infections, and activate TB.
In 2008, the FDA announced that 45 people on Humira, Enbrel, Remicade, and Cimzia died from fungal diseases, and investigated Humira’s links to lymphoma, leukemia, and melanoma in children. This year, the FDA warned that the drugs can cause “a rare cancer of white blood cells” in young people, and the Journal of the American Medical Association (JAMA) warned of “potentially fatal Legionella and Listeria infections.”
Immune-suppressing drugs are also dangerous to the pocketbook. One injection of Remicade costs up to $2,500; a month’s supply of Enbrel costs $1,500; and a year’s supply of Humira costs up to $20,000.
Once upon a time, RA was diagnosed from the presence of “rheumatoid factor” and inflammation. But, thanks to Pharma’s supply-driven marketing, stiffness and pain are all that are required for the diagnosis today. (Athletes and people born before 1970 — line forms to the left!)
In addition to diagnostic wiggle room and a catchy name, RA has other blockbuster disease requirements. It will “only get worse” if untreated, says WebMD, and it is often “misdiagnosed” and underreported, says Abbott’s Heather Mason, because “people often don’t know what they have for a while.”
So serious a disease, it costs over $20,000 a year to treat but so subtle you may not know you have it? RA sounds like a blockbuster.
Fibromyalgia
Another underreported disease is fibromyalgia, characterized by widespread. unexplained bodily pain. Fibromyalgia is “almost a textbook definition of an unmet medical need,” says Ian Read of Pfizer, which makes the first drug to be approved for fibromyalgia, the seizure pill Lyrica. Pfizer gave nonprofit groups $2.1 million in 2008 to “educate” doctors about fibromyalgia and financed PSAs (pharma service announcements) depicting sufferers describing their symptoms without mentioning a drug. Lyrica now makes $3 billion a year.
Still, Lyrica has to fight Cymbalta, the first antidepressant to be approved for fibromyalgia. Eli Lilly prepositioned Cymbalta for the physical “pain” of depression in a campaign called “Depression Hurts” before the fibromyalgia approval. Treatment of a fibromyalgia patients with either Lyrica or Cymbalta hovers around $10,000, say medical journals.
Pharma and Wall Street may be happy with fibromyalgia drugs, but patients aren’t. On askapatient.com, the drug-rating website, patients on Cymbalta reported chills, jaw problems, electrical “pings” in their brain, and eye problems. This year, four patients reported the urge to kill themselves, a frequently reported side effect of Cymbalta. Lyrica users on askapatient reported memory loss, confusion, extreme weight gain, hair loss, impaired driving, disorientation, twitching, and worse. Some patients take both drugs.
SLEEP DISORDERS
Middle of the Night Insomnia
Sleep disorders are a goldmine for Pharma because everyone sleeps — or watches TV when they can’t. To churn the insomnia market, Pharma rolls out subcategories of insomnia, such as chronic, acute, transient, initial, delayed-onset, terminal, early-morning, menopausal, and the master category of nonrestful sleep. This fall, Pharma rolled out a new version of Ambien for “middle-of-the-night” insomnia called Intermezzo, even though Ambien is paradoxically notorious for middle-of-the-night awakenings: people “waking up” in an Ambien blackout and walking, talking, driving, making phone calls, and eating food.
Many became aware of Ambien’s “lights-on-nobody-home” effect when former Rhode Island Representative Patrick Kennedy drove to Capitol Hill to “vote” at 2:45 a.m. in 2006 on Ambien and crashed his Mustang. But it was Ambien’s EWI effect — eating while intoxicated — not DWIs that gave the pill its worst rap. Fit and sexy people awoke amid mountains of pizza, Krispy Kreme, and Häagen-Dazs cartons, their contents consumed by their evil twin on Ambien.
Excessive Sleepiness and Shift Work Sleep Disorder
Needless to say, people with insomnia won’t be bright-eyed and bushy-tailed the following day — whether they didn’t sleep or whether they have sleeping pill residues in their system. In fact, they are actually suffering from the underrecognized and underreported epidemic of Excessive Daytime Sleepiness. The main medical causes of EDS or ES are sleep apnea and narcolepsy, but last year Pharma rolled out a lifestyle-caused “Shift Work Sleep Disorder.” (No, it doesn’t meant you can’t sleep because your partner “shifts” in his or her sleep.) Ads for Provigil, a Schedule IV stimulant that treats EDS along with Nuvigil show a judge in his black robe, nodding out on the job, with the headline “Struggling to Fight the Fog?” (“Yo! Your Honor! I’m trying to plead!”).
Of course wakefulness agents contribute to insomnia, which contributes to wakefulness problems in a kind of perpetual pharmaceutical jet lag. In fact, the sleeping pill/alertness aid habit is so common, it threatens to create a new meaning for “AA” — Adderall and Ambien!
Insomnia That Is Really Depression
Sleep disorders have also given a new lease on life to antidepressants. Doctors now prescribe more antidepressants for insomnia than they do sleeping pills, according to CNN. They also often combine them, since “insomnia and depression often occur together, but which is the cause and which is the symptom is often unclear.”
WebMD agrees with doubling the drugs. “Depressed patients with insomnia who were treated with both an antidepressant and a sleep medication fared better than those treated only with antidepressants,” it writes. Ka-ching!
In fact, many of the new blockbuster diseases from adult ADHD and RA to fibromyalgia are treated with new drugs piled on top of existing ones that aren’t working, a Pharma contrivance called polypharmacy. It brings to mind the store owner who says, “I know that 50 percent of my advertising is wasted — I just don’t know which 50 percent.”
Martha Rosenberg frequently writes about the impact of the pharmaceutical, food, and gun industries on public health. Her work has appeared in the Boston Globe, San Francisco Chronicle, Chicago Tribune, and other outlets.
© 2011 Independent Media Institute. All rights reserved.
View this story online at: http://www.alternet.org/story/153332/
|
On December 21, 2012, the
